DOCSLIB.ORG

Changes in Glutathione Content in Liver Diseases: an Update

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Changes in Glutathione Content in Liver Diseases: an Update antioxidants Review Changes in Glutathione Content in Liver Diseases: An Update Mariapia Vairetti , Laura Giuseppina Di Pasqua * , Marta Cagna, Plinio Richelmi, Andrea Ferrigno * and Clarissa Berardo Unit of Cellular and Molecular Pharmacology and Toxicology, Department of Internal Medicine and Therapeutics, University of Pavia, 27100 Pavia, Italy; [email protected] (M.V.); [email protected] (M.C.); [email protected] (P.R.); [email protected] (C.B.) * Correspondence: [email protected] (L.G.D.P.); [email protected] (A.F.); Tel.: +39-0382-98687 (L.G.D.P.); +39-0382-986451 (A.F.) Abstract: Glutathione (GSH), a tripeptide particularly concentrated in the liver, is the most important thiol reducing agent involved in the modulation of redox processes. It has also been demonstrated that GSH cannot be considered only as a mere free radical scavenger but that it takes part in the network governing the choice between survival, necrosis and apoptosis as well as in altering the function of signal transduction and transcription factor molecules. The purpose of the present review is to provide an overview on the molecular biology of the GSH system; therefore, GSH synthesis, metabolism and regulation will be reviewed. The multiple GSH functions will be described, as well as the importance of GSH compartmentalization into distinct subcellular pools and inter-organ transfer. Furthermore, we will highlight the close relationship existing between GSH content and the pathogenesis of liver disease, such as non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease (ALD), chronic cholestatic injury, ischemia/reperfusion damage, hepatitis C virus (HCV), hepatitis B virus (HBV) and hepatocellular carcinoma. Finally, the potential therapeutic benefits of Citation: Vairetti, M.; Di Pasqua, GSH and GSH-related medications, will be described for each liver disorder taken into account. L.G.; Cagna, M.; Richelmi, P.; Ferrigno, A.; Berardo, C. Changes in Keywords: glutathione; liver; Nrf2 Glutathione Content in Liver Diseases: An Update. Antioxidants 2021, 10, 364. https://doi.org/ 10.3390/antiox10030364 1. Introduction Glutathione (GSH), or L-γ-glutamyl-L-cysteinyl-glycine, is a tripeptide present in Academic Editor: Greg Barritt mammalian cells at surprisingly high levels (1–10 mM) and particularly concentrated in the liver [1,2]. The thiol group of cysteine is responsible for GSH biological activity: Received: 2 February 2021 GSH is considered the most important cellular redox buffer and major defender against Accepted: 24 February 2021 Published: 28 February 2021 oxidative stress. GSH is oxidized into glutathione disulfide (GSSG), which is actually two GSH molecules bound together at the sulfur atoms (Figure1). The oxidized form is Publisher’s Note: MDPI stays neutral reconverted into GSH by the NADPH-dependent enzyme glutathione reductase (GR) [3]. with regard to jurisdictional claims in The GSH:GSSG ratio is often used as a marker of cellular toxicity. Under normal conditions, published maps and institutional affil- the molar GSH:GSSG ratio is around 100:1; during stress, this ratio has been shown to iations. decrease to 10:1 and even 1:1 [4–8]. It has been demonstrated that GSH has multiple roles in cell physiology, including: (i) direct scavenging of reactive oxygen species (ROS), nitric oxide (NO) and its derivatives (RNS), resulting in the protection of the electron transport chain, DNA, lipids and proteins; (ii) indirect neutralization of intoxicants; (iii) S-gluta-thionylation of protein Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. thiol groups; (iv) regulation of cell cycle progression and apoptosis. This article is an open access article From these considerations, it emerges that GSH cannot be considered a mere free distributed under the terms and radical scavenger but that it has a weighty role in the network governing the choice conditions of the Creative Commons between survival, necrosis and apoptosis [9,10] as well as in cell signaling [10,11] and Attribution (CC BY) license (https:// metabolism [3,12]. creativecommons.org/licenses/by/ The present review will focus on the molecular biology of the GSH system. GSH 4.0/). synthesis, metabolism and regulation will be reviewed; the multiple GSH functions will be Antioxidants 2021, 10, 364. https://doi.org/10.3390/antiox10030364 https://www.mdpi.com/journal/antioxidants Antioxidants 2021, 10, x FOR PEER REVIEW 2 of 39 Antioxidants 2021, 10, 364 2 of 39 The present review will focus on the molecular biology of the GSH system. GSH syn- thesis, metabolism and regulation will be reviewed; the multiple GSH functions will be described, as well as GSH compartmentalization and interorgan interorgan transfer. Finally, the role of GSH in pathogenesis and potential therapeutictherapeutic approaches will bebe alsoalso highlighted.highlighted. Figure 1. Glutathione (GSH) structure and balance between GSH and glutathione disulfide (GSSG). Figure 1. Glutathione (GSH) structure and balance between GSH and glutathione disulfide (2.GSSG Glutathione). Synthesis and Metabolism The main source of GSH is the liver, which has the unique ability to synthesize cysteine, 2. Glutathione Synthesis and Metabolism a GSH precursor, from endogenous sources through the trans-sulphuration pathway [13], or toThe obtain main it from source protein of GSH breakdown is the liver, and which food. has GSH the availability unique ability in hepatocytes to synthesize depends cys- teine,on the a membrane GSH precursor, transport from of endogenous cysteine itself, sources cystine through and methionine the trans-sulphuration [2]. In fact, a goodpath- wayamount [13] of, or GSH to obtain is indirectly it from obtained protein breakdown from methionine; and food. methionine GSH availability deficiency in has hepato- been cytesfound depends to induce on the a reduction membrane in transport GSH availability, of cysteine especially itself, cystine in the and liver methionine [14,15]. [2] As. In a fact,consequence, a good amount the liver of playsGSH is a centralindirectly role obtained in maintaining from methionine; interorgan homeostasismethionine deficiency of GSH by hasexporting been found nearly to all induce of the synthesizeda reduction in GSH GSH into availability, plasma and especially bile; in fact, in the the liver has[14,15] the. Ashighest a consequence, capacity for the GSH liver efflux plays through a central its basolateralrole in maintaining and apical interorgan poles [13]. homeostasis Consequently, of GSHan alteration by exporting of the nearly hepatic all ability of the tosynthesized synthesize GSH or export into plasma GSH has and an bile; impact in fact, on systemicthe liver hasGSH the homeostasis highest capacity [2]. for GSH efflux through its basolateral and apical poles [13]. Con- sequently,The first an stepalteration in GSH of synthesisthe hepatic is catalyzedability to bysynthesizeL-glutamate or exportL-cysteine GSHγ has-ligase an impact (GCL), onresulting systemic in theGSH formation homeostasis of γ -glutamyl-cysteine.[2]. GCL is a heterodimer constituted by a catalyticThe monomerfirst step in (GCLC) GSH synthesis and a modifier is catalyzed monomer by L-glutamate (GCLM). GCLC L-cysteine is sensitive γ-ligase to (GCL), GSH- resultinginduced feedback in the formation inhibition. of GCLMγ-glutamyl is enzymatically-cysteine. GCL inert; is however,a heterodimer in the constituted dimer it reduces by a catalyticthe inhibitory monomer feedback (GCLC) response and a tomodifier GSH [2 ].monomer GCL expression (GCLM). responds GCLC is tosensitive oxidative to stressGSH- inducedand is positively feedbackregulated inhibition. by GCLM nuclear is factorenzymatically erythroid inert; 2-related however, factor in 2the (Nrf2) dimer [16 it– 19re-]. ducesNrf2 works the inhibitory in combination feedback with response small avianto GSH musculoaponeurotic [2]. GCL expression fibrosarcoma responds to oncogeneoxidative stresshomolog and (MAF) is positively proteins: regulated together by they nuclear recognize factor and erythroid bind antioxidant 2-related factor response 2 (Nrf2) elements [16– (ARE)19]. Nrf2 in works promoters in combination of antioxidant with enzyme small avian genes musculoaponeurotic (phase 2 enzymes suchfibro assarcoma glutathione onco- geneS-Transferase homolog (GST),(MAF) UDP-glucorosyl proteins: together transferase they recognize and superoxide and bind antioxidant dismutase (SOD),response GSH el- peroxidaseements (ARE) (GPx) in promoters and catalase of antioxidant (CAT), sulfiredoxin enzyme 1genes and Thioredoxin(phase 2 enzymes reductase such 1as [16 gluta-–19]. thioneNrf2 is S inhibited-Transferase by Kelch-like(GST), UDP ECH-associated-glucorosyl transferase protein 1and (Keap1): superoxide specifically, dismu ittase increases (SOD), GSHNrf2 peroxidase proteasome-mediated (GPx) and catalase degradation (CAT) [20, s,21ulfiredoxin]. Electrophilic 1 and agentsThioredoxin and antioxidants reductase 1 [16induce–19]. conformational Nrf2 is inhibited changes by Kelch in- Keap1,like ECH thus-associated impeding protein the binding 1 (Keap1): with specifically, Nrf2 leading it increasesto the consequent Nrf2 proteasome migration-mediated of the nucleardegradation factor [20,21] in the. Electrophilic nucleus, where agents it can and exert antiox- its idantsfunction induce [22]. conformational changes in Keap1, thus impeding the binding with Nrf2 leadingThe to second the consequent step in GSH
Load more

Recommended publications
  • Specifications of Approved Drug Compound Library
    Annexure-I : Specifications of Approved drug compound library The compounds should be structurally diverse, medicinally active, and cell permeable Compounds should have rich documentation with structure, Target, Activity and IC50 should be known Compounds which are supplied should have been validated by NMR and HPLC to ensure high purity Each compound should be supplied as 10mM solution in DMSO and at least 100µl of each compound should be supplied. Compounds should be supplied in screw capped vial arranged as 96 well plate format.
    [Show full text]
  • Mechanistic Insights on the Reduction of Glutathione Disulfide by Protein Disulfide Isomerase
    Mechanistic insights on the reduction of glutathione disulfide by protein disulfide isomerase Rui P. P. Nevesa, Pedro Alexandrino Fernandesa, and Maria João Ramosa,1 aUnidade de Ciências Biomoleculares Aplicadas, Rede de Química e Tecnologia, Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade do Porto, 4169-007 Porto, Portugal Edited by Donald G. Truhlar, University of Minnesota, Minneapolis, MN, and approved May 9, 2017 (received for review November 22, 2016) We explore the enzymatic mechanism of the reduction of glutathione of enzymes, which are responsible for the reduction and isomer- disulfide (GSSG) by the reduced a domain of human protein disulfide ization of disulfide bonds, through thiol-disulfide exchange. isomerase (hPDI) with atomistic resolution. We use classical molecular dynamics and hybrid quantum mechanics/molecular mechanics cal- Structure and Function of PDI culations at the mPW1N/6–311+G(2d,2p):FF99SB//mPW1N/6–31G(d): Human protein disulfide isomerase (hPDI) is a U-shaped enzyme FF99SB level. The reaction proceeds in two stages: (i) a thiol-disulfide with 508 residues. Its tertiary structure is composed of four exchange through nucleophilic attack of the Cys53-thiolate to the thioredoxin-like domains (a, b, b′,anda′) and a fifth tail-shaped c GSSG-disulfide followed by the deprotonation of Cys56-thiol by domain (Fig. 1) (14, 15). The maximum activity of hPDI is observed Glu47-carboxylate and (ii) a second thiol-disulfide exchange between when all domains of PDI contribute synergistically to its function (16). the Cys56-thiolate and the mixed disulfide intermediate formed in Similar to thioredoxin, the a and a′ domains have a catalytic the first step.
    [Show full text]
  • Degradation of Glutathione in Plant Cells
    Degradation of Glutathione in Plant Cells: Evidence against the Participation of a y-Glutamyltranspeptidase Reinhard Steinkamp and Heinz Rennenberg Botanisches Institut der Universität zu Köln, Gyrhofstr. 15, D-5000 Köln 41, Bundesrepublik Deutschland Z. Naturforsch. 40c, 29 — 33 (1985); received August 31/October 4, 1984 Tobacco, Glutathione Catabolism, y-Glutamylcysteine, y-Glutamyltranspeptidase, y-Glutamyl- cyclotransferase When y-glutamyltranspeptidase activity in tobacco cells was measured using the artificial substrate y-glutamyl-/?-nitroanilide, liberation of p-nitroaniline was not reduced, but stimulated by addition of glutathione. Therefore, glutathione was not acting as a donator, but as an acceptor of y-glutamyl moieties in the assay mixture, suggesting that y-glutamyltranspeptidase is not participating in degradation of glutathione. Feeding experiments with [^S-cysJglutathione sup­ ported this conclusion. When tobacco cells were supplied with this peptide as sole sulfur source, glutathione and y-glutamylcysteine were the only labelled compounds found inside the cells. The low rate of uptake of glutathione apparently prevented the accumulation of measurable amounts of radioactivity in the cysteine pool. A y-glutamylcyclotransferase, responsible for the conversion of y-glutamylcysteine to 5-oxo-proline and cysteine was found in ammonium sulfate precipitates of tobacco cell homogenates. The enzyme showed high activities with y-glutamylmethionine and y-glutamylcysteine, but not with other y-glutamyldipeptides or glutathione. From these and previously published experiments [(Rennenberg et al., Z. Naturforsch. 3 5 c, 70 8 -7 1 1 (1980)], it is concluded that glutathione is degraded in tobacco cells via the following pathway: y-glu-cys- gly —> y-glu-cys ->• 5-oxo-proline -* glu. Introduction the cysteine conjugate by the action of a y-gluta­ myltranspeptidase (Fig.
    [Show full text]
  • (Esi Scheme) Laxminagar, Ajmer Road, Jaipur-302006
    DIRECTORATE, MEDICAL & HEALTH SERVICES, (E.S.I. SCHEME) LAXMINAGAR, AJMER ROAD, JAIPUR-302006 Tel/Fax 0141-2223572,www.health.rajasthan.gov.in/esi E-Mail [email protected],[email protected] Ref. No. F434/ESI/Store/LabEmp/2017/5540 Dated:01/11/2017 E- Tender Document For “E- Tender forAnalysis of Drugs, Cotton, Gauzes, Bandage & Other items” For The Office of the Director cum Ex-officio Dy. Secretary, Medical & Health Services ESI Scheme Rajasthan, Laxmi Nagar, Ajmer Road, Jaipur & attached ESIS Institutions in Rajasthan ( for the period of two years from the date of award. ) ( Non-transferable ) Price of Tender Document Rs. 2000/- Last date & time of submission of Technical & Financial Bids is 11.12.17 at 1:30 pm Date & time of online opening of Technical Bid is 11.12.17 at 3:00 pm Visit Us At http://sppp.raj.nic.in, www.dipronline.org, http://eproc.rajasthan.gov.in, www.health.rajasthan.gov.in/esi Our Address: DIRECTORATE, MEDICAL & HEALTH SERVICES, (E.S.I. SCHEME) LAXMINAGAR, AJMER ROAD, JAIPUR-302006 1/71 DIRECTORATE, MEDICAL & HEALTH SERVICES, (E.S.I. SCHEME) LAXMINAGAR, AJMER ROAD, JAIPUR-302006 Tel/Fax 0141-2223572,www.health.rajasthan.gov.in/esi E-Mail [email protected],[email protected] Ref.No.F434/ESI/Store/LabEmp/2017/ 5540 Dated:01/11/2017 E-bids in two separate bids (Technical & Financial) for the Empanelment of Analytic Testing Laboratories For The Test and Analysis of drugs, cotton, bandage, gauze & other items. Brief Details of E-Tender Estimated Cost : Rs 50 lacs EMD (Bid Security)Rs 100000/- RISL processing fees Rs 1000/- Cost of the Tender Document Rs 2000/- Performance Security 5% of contract value Services Required:- The service of analysis of drugs, cotton, gauze, bandages & other items are required in the office of the Director cum Ex- officio Dy.
    [Show full text]
  • NAC and Vitamin D Restore CNS Glutathione in Endotoxin-Sensitized Neonatal Hypoxic-Ischemic Rats
    antioxidants Article NAC and Vitamin D Restore CNS Glutathione in Endotoxin-Sensitized Neonatal Hypoxic-Ischemic Rats Lauren E. Adams 1,†, Hunter G. Moss 2,† , Danielle W. Lowe 3,† , Truman Brown 2, Donald B. Wiest 4, Bruce W. Hollis 1, Inderjit Singh 1 and Dorothea D. Jenkins 1,* 1 Department of Pediatrics, 10 McLellan Banks Dr, Medical University of South Carolina, Charleston, SC 29425, USA; [email protected] (L.E.A.); [email protected] (B.W.H.); [email protected] (I.S.) 2 Center for Biomedical Imaging, Department of Radiology, Medical University of South Carolina, 68 President St. Room 205, Charleston, SC 29425, USA; [email protected] (H.G.M.); [email protected] (T.B.) 3 Department of Psychiatry, Medical University of South Carolina, 67 Presidents St., MSC 861, Charleston, SC 29425, USA; [email protected] 4 Department of Pharmacy and Clinical Sciences, College of Pharmacy, Medical University of South Carolina, Charleston, SC 29425, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-843-792-2112 † Three first authors contributed equally to this work. Abstract: Therapeutic hypothermia does not improve outcomes in neonatal hypoxia ischemia (HI) complicated by perinatal infection, due to well-described, pre-existing oxidative stress and neuroin- flammation that shorten the therapeutic window. For effective neuroprotection post-injury, we must first define and then target CNS metabolomic changes immediately after endotoxin-sensitized HI (LPS-HI). We hypothesized that LPS-HI would acutely deplete reduced glutathione (GSH), indicating overwhelming oxidative stress in spite of hypothermia treatment in neonatal rats. Post-natal day 7 Citation: Adams, L.E.; Moss, H.G.; rats were randomized to sham ligation, or severe LPS-HI (0.5 mg/kg 4 h before right carotid artery Lowe, D.W.; Brown, T.; Wiest, D.B.; ligation, 90 min 8% O2), followed by hypothermia alone or with N-acetylcysteine (25 mg/kg) and Hollis, B.W.; Singh, I.; Jenkins, D.D.
    [Show full text]
  • Sulfhydryl Reduction of Methylene Blue with Reference to Alterations in Malignant Neoplastic Disease
    Sulfhydryl Reduction of Methylene Blue With Reference to Alterations in Malignant Neoplastic Disease Maurice M. Black, M. D. (From the Department of Biochemistry, New York Medical College, New York 29, N. t;., and the Brooklyn Cancer Institute, Brooklyn 9, N. Y.) (Received for publication May 8, 1947) A significant decrease in methylene blue re- reactivity is less than half that of the cysteine. It is ducing power of plasma from patients with malig- noteworthy also that the resultant leuco mixture nant neoplastic disease was previously reported did not revert back to colored methylene blue on (1). At that time it was suggested that change in a cooling, as was the case with methylene blue re- reducing group of the albumin molecule was a duction by plasma. likely source of this alteration. Similar conclusions Similar relationships were investigated between were reported also by Savignac and associates (7) cysteine and different concentrations of methylene as the result of analogous studies. blue. As seen in Fig. 2, similar curves are obtained, In an attempt to evaluate the effect of the sulf- but the position of the curve on the graph varies hydryl group on the reduction of methylene blue, a with the concentration of the methylene blue used. study was undertaken with various compounds of It should be noted that there is no appreciable known -SH and S-S structures. In addition, an difference in the reducing time of methylene blue attempt was made to establish a standard method on varying the concentrations between 0.10 per of calibration of various lots of methylene blue, so cent and 0.2 per cent, although 0.08 per cent shows that more uniform results would be possible in the a decided difference.
    [Show full text]
  • |||||||||||||III US005202354A United States Patent (19) (11) Patent Number: 5,202,354 Matsuoka Et Al
    |||||||||||||III US005202354A United States Patent (19) (11) Patent Number: 5,202,354 Matsuoka et al. 45) Date of Patent: Apr. 13, 1993 (54) COMPOSITION AND METHOD FOR 4,528,295 7/1985 Tabakoff .......... ... 514/562 X REDUCING ACETALDEHYDE TOXCTY 4,593,020 6/1986 Guinot ................................ 514/811 (75) Inventors: Masayoshi Matsuoka, Habikino; Go OTHER PUBLICATIONS Kito, Yao, both of Japan Sprince et al., Agents and Actions, vol. 5/2 (1975), pp. 73) Assignee: Takeda Chemical Industries, Ltd., 164-173. Osaka, Japan Primary Examiner-Arthur C. Prescott (21) Appl. No.: 839,265 Attorney, Agent, or Firn-Wenderoth, Lind & Ponack 22) Filed: Feb. 21, 1992 (57) ABSTRACT A novel composition and method are disclosed for re Related U.S. Application Data ducing acetaldehyde toxicity, especially for preventing (63) Continuation of Ser. No. 13,443, Feb. 10, 1987, aban and relieving hangover symptoms in humans. The com doned. position comprises (a) a compound of the formula: (30) Foreign Application Priority Data Feb. 18, 1986 JP Japan .................................. 61-34494 51) Int: C.5 ..................... A01N 37/00; A01N 43/08 52 U.S. C. ................................. ... 514/562; 514/474; 514/81 wherein R is hydrogen or an acyl group; R' is thiol or 58) Field of Search ................ 514/557, 562, 474,811 sulfonic group; and n is an integer of 1 or 2, (b) ascorbic (56) References Cited acid or a salt thereof and (c) a disulfide type thiamine derivative or a salt thereof. The composition is orally U.S. PATENT DOCUMENTS administered, preferably in the form of tablets. 2,283,817 5/1942 Martin et al.
    [Show full text]
  • As Sensitive Plasma Biomarkers of Oxidative Stress Received: 22 June 2018 Xiaoyun Fu1,2, Shelby A
    www.nature.com/scientificreports OPEN Cysteine Disulfdes (Cys-ss-X) as Sensitive Plasma Biomarkers of Oxidative Stress Received: 22 June 2018 Xiaoyun Fu1,2, Shelby A. Cate1, Melissa Dominguez1, Warren Osborn1, Tahsin Özpolat 1, Accepted: 6 November 2018 Barbara A. Konkle1,2, Junmei Chen1 & José A. López1,2 Published: xx xx xxxx We developed a high-throughput mass spectrometry–based method to simultaneously quantify numerous small-molecule thiols and disulfdes in blood plasma. Application of this assay to analyze plasma from patients with known oxidative stress (sickle cell disease and sepsis) and from a patient with sickle cell disease treated with the antioxidant N-acetylcysteine suggests that cysteine disulfdes, in particular protein-bound cysteine, serve as sensitive plasma biomarkers for the extent of oxidative stress and efectiveness of antioxidant treatment. Oxidative stress accompanies a wide variety of diseases1, including sickle cell disease (SCD), HIV/AIDS, and rheumatoid arthritis, and antioxidant therapy is emerging as a pharmacological strategy for treating diseases in which oxidative stress is known or suspected to be elevated2. Te ability to measure oxidative stress quantitatively is important for understanding disease mechanisms and monitoring the efectiveness of antioxidant treatments. Among biomarkers of oxidative stress, the ratio of reduced glutathione (GSH) to glutathione disulfde (GSSG) is frequently measured in various cell types, owing to the millimolar intracellular concentrations of these glu- tathione species and the broad availability of assays for their measurement, including many that are commercially available1,3,4. Despite these advantages, GSH/GSSG is not well suited as a plasma biomarker of oxidative stress due to the low plasma concentrations of GSH species, which are usually in the low micromolar range, and the low sensitivity of the assays.
    [Show full text]
  • Merit of an Ursodeoxycholic Acid Clinical Trial in COVID-19 Patients
    Viewpoint Merit of an Ursodeoxycholic Acid Clinical Trial in COVID-19 Patients Subbaya Subramanian 1 , Tinen Iles 1, Sayeed Ikramuddin 1 and Clifford J. Steer 2,* 1 Department of Surgery, University of Minnesota, Minneapolis, MN 55455, USA; [email protected] (S.S.); [email protected] (T.I.); [email protected] (S.I.) 2 Departments of Medicine and Genetics, Cell Biology and Development, University of Minnesota, Minneapolis, MN 55455, USA * Correspondence: [email protected]; Tel.: +1-612-624-6648 Received: 28 May 2020; Accepted: 17 June 2020; Published: 19 June 2020 Abstract: Corona Virus Disease 2019 (COVID-19) has affected over 8 million people worldwide. We underscore the potential benefits of conducting a randomized open-label unblinded clinical trial to evaluate the role of ursodeoxycholic acid (UDCA) in the treatment of COVID-19. Some COVID-19 patients are characterized with cytokine storm syndrome that can cause severe and irreversible damage to organs leading to multi-organ failure and death. Therefore, it is critical to control both programmed cell death (apoptosis) and the hyper-immune inflammatory response in COVID-19 patients to reduce the rising morbidity and mortality. UDCA is an existing drug with proven safety profiles that can reduce inflammation and prevent cell death. National Geographic reported that, “China Promotes Bear Bile as Coronavirus Treatment”. Bear bile is rich in UDCA, comprising up to 40–50% of the total bile acid. UDCA is a logical and attainable replacement for bear bile that is available in pill form and merits clinical trial consideration. Keywords: Coronavirus; COVID-19; cytokine storm; ursodeoxycholic acid; clinical trial Coronavirus SARS-CoV-2 as the cause of COVID-19 (Corona Virus Disease 2019) has affected over 8 million people worldwide.
    [Show full text]
  • Pharmacological Treatment Options for Alcohol Use Disorder*
    Dusunen Adam The Journal of Psychiatry and Neurological Sciences 2015;28:283-300 Editorial / Editoryal DOI: 10.5350/DAJPN20152804001 Pharmacological Treatment Cuneyt Evren1, Muge Bozkurt2 1Assoc. Prof. Dr., 2Psychiatrist, Bakirkoy Training and Options for Alcohol Use Research Hospital for Psychiatry, Neurology and Neurosurgery, Alcohol and Drug Research, Treatment and Training Center (AMATEM), Disorder* Istanbul - Turkey Address reprint requests to / Yazışma adresi: Assoc. Prof. Dr. Cuneyt Evren, Bakirkoy Training and Research Hospital for Psychiatry, Neurology and Neurosurgery, Alcohol and Drug Research, Treatment and Training Center (AMATEM), Istanbul, Turkey Phone / Telefon: +90-212-409-1515/2111, Fax / Faks: +90-212-409-1590, E-mail address / Elektronik posta adresi: [email protected] *Abridged version of the “Therapeutic Guideline for Alcohol Use Disorder” prepared by the Working Group Therapeutic Guideline for Alcohol Use Disorder. PHARMACOLOGICAL TREATMENT assess information obtained from studies regarding OPTIONS FOR ALCOHOL USE DISORDER drug treatments used in clinical practice today, which are summarized in Table 1. However, when examining Alcohol Use Disorder (AUD) and other alcohol- study results for pharmacological treatments, we related health problems are a significant public health immediately have to remember that all of those issue all over the world. The World Health Organization (WHO) reports that each year 3.3 million people lose Table 1: Drugs used for the therapy of alcohol use their lives due to harmful alcohol use, with 5.9% of all disorder (AUD) deaths being related to alcohol consumption (1). It has Drugs for AUD approved in Turkey been estimated that in 2010, the economic burden of Disulfiram Naltrexone alcohol-related costs was 155.8 billion Euro, of which Acamprosate 60% were connected to alcohol addiction (2).
    [Show full text]
  • 1 Thiol Oxidase Ability of Copper Ion Is Specifically
    THIOL OXIDASE ABILITY OF COPPER ION IS SPECIFICALLY RETAINED UPON CHELATION BY ALDOSE REDUCTASE Francesco Balestri, Roberta Moschini, Mario Cappiello, Umberto Mura and Antonella Del- Corso. University of Pisa, Department of Biology, Biochemistry Unit, via San Zeno, 51, Pisa, 56123, Italy. Corresponding author: Antonella Del-Corso, University of Pisa, Department of Biology, Biochemistry Unit, via San Zeno, 51, Pisa, 56123, Italy; Phone: +39.050.2211454; Fax: +39.050.2211460 E-mail: [email protected] Acknowledgements. This work was supported by Pisa University, PRA 2015. We are indebted to Dr. G. Pasqualetti and Dr. R. Di Sacco (veterinary staff of Consorzio Macelli S. Miniato, Pisa) for their valuable co-operation in the bovine lenses collection. 1 Abstract Bovine lens aldose reductase is susceptible to a copper mediated oxidation, leading to the generation of a disulfide bridge with the concomitant incorporation of two equivalents of the metal and inactivation of the enzyme. The metal complexed by the protein remains redox- active, being able to catalyze the oxidation of different physiological thiol compounds. The thiol oxidase activity displayed by the enzymatic form carrying one equivalent of copper ion (Cu1-AR) has been characterized. The efficacy of Cu1-AR in catalyzing thiol oxidation is essentially comparable to the free copper in terms of both thiol concentration and pH effect. On the contrary, the two catalysts are differently affected by temperature. The specificity of the AR-bound copper towards thiols is highlighted being Cu1-AR completely ineffective in promoting the oxidation of both low density lipoprotein and ascorbic acid. Keywords: aldose reductase; copper; oxidative stress; thiol oxidase; 2 Introduction The role of transition metals in inducing cell damage has been widely recognized [1, 2].
    [Show full text]
  • OCALIVA™ (Obeticholic Acid) Oral
    PHARMACY COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 9/15/2016 SECTION: DRUGS LAST REVIEW DATE: 8/19/2021 LAST CRITERIA REVISION DATE: 8/19/2021 ARCHIVE DATE: OCALIVA™ (obeticholic acid) oral Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage Guideline must be read in its entirety to determine coverage eligibility, if any. This Pharmacy Coverage Guideline provides information related to coverage determinations only and does not imply that a service or treatment is clinically appropriate or inappropriate. The provider and the member are responsible for all decisions regarding the appropriateness of care. Providers should provide BCBSAZ complete medical rationale when requesting any exceptions to these guidelines. The section identified as “Description” defines or describes a service, procedure, medical device or drug and is in no way intended as a statement of medical necessity and/or coverage. The section identified as “Criteria” defines criteria to determine whether a service, procedure, medical device or drug is considered medically necessary or experimental or investigational. State or federal mandates, e.g., FEP program, may dictate that any drug, device or biological product approved by the U.S. Food and Drug Administration (FDA) may not be considered experimental or investigational and thus the drug, device or biological product may be assessed only on the basis of medical necessity. Pharmacy Coverage Guidelines are subject to change as new information becomes available. For purposes of this Pharmacy Coverage Guideline, the terms "experimental" and "investigational" are considered to be interchangeable. BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans.
    [Show full text]